The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea

Cheolsu Kim, Ho Sup Lee, Chang Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho Jin Shin, Ji Hyun Lee, Yong Park, Jae Cheol Jo, Young Rok Do, Yeung Chul Mun

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, ß2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.

Original languageEnglish
Pages (from-to)675-683
Number of pages9
JournalKorean Journal of Internal Medicine
Volume30
Issue number5
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

Thalidomide
Korea
Multiple Myeloma
Induction Chemotherapy
Stem Cell Transplantation
Confidence Intervals
Survival
Republic of Korea
Lymphocyte Count
Platelet Count
C-Reactive Protein
Disease-Free Survival
Albumins
Multivariate Analysis

Keywords

  • Inflammation
  • Multiple myeloma
  • Prognosis
  • Thalidomide

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. / Kim, Cheolsu; Lee, Ho Sup; Min, Chang Ki; Lee, Je Jung; Kim, Kihyun; Yoon, Dok Hyun; Eom, Hyeon Seok; Lee, Hyewon; Lee, Won Sik; Shin, Ho Jin; Lee, Ji Hyun; Park, Yong; Jo, Jae Cheol; Do, Young Rok; Mun, Yeung Chul.

In: Korean Journal of Internal Medicine, Vol. 30, No. 5, 01.09.2015, p. 675-683.

Research output: Contribution to journalArticle

Kim, C, Lee, HS, Min, CK, Lee, JJ, Kim, K, Yoon, DH, Eom, HS, Lee, H, Lee, WS, Shin, HJ, Lee, JH, Park, Y, Jo, JC, Do, YR & Mun, YC 2015, 'The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea', Korean Journal of Internal Medicine, vol. 30, no. 5, pp. 675-683. https://doi.org/10.3904/kjim.2015.30.5.675
Kim, Cheolsu ; Lee, Ho Sup ; Min, Chang Ki ; Lee, Je Jung ; Kim, Kihyun ; Yoon, Dok Hyun ; Eom, Hyeon Seok ; Lee, Hyewon ; Lee, Won Sik ; Shin, Ho Jin ; Lee, Ji Hyun ; Park, Yong ; Jo, Jae Cheol ; Do, Young Rok ; Mun, Yeung Chul. / The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. In: Korean Journal of Internal Medicine. 2015 ; Vol. 30, No. 5. pp. 675-683.
@article{d0977930a9144a59bc19415a5e9842ef,
title = "The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea",
abstract = "Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, {\ss}2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95{\%} confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95{\%} CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95{\%} CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.",
keywords = "Inflammation, Multiple myeloma, Prognosis, Thalidomide",
author = "Cheolsu Kim and Lee, {Ho Sup} and Min, {Chang Ki} and Lee, {Je Jung} and Kihyun Kim and Yoon, {Dok Hyun} and Eom, {Hyeon Seok} and Hyewon Lee and Lee, {Won Sik} and Shin, {Ho Jin} and Lee, {Ji Hyun} and Yong Park and Jo, {Jae Cheol} and Do, {Young Rok} and Mun, {Yeung Chul}",
year = "2015",
month = "9",
day = "1",
doi = "10.3904/kjim.2015.30.5.675",
language = "English",
volume = "30",
pages = "675--683",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "5",

}

TY - JOUR

T1 - The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea

AU - Kim, Cheolsu

AU - Lee, Ho Sup

AU - Min, Chang Ki

AU - Lee, Je Jung

AU - Kim, Kihyun

AU - Yoon, Dok Hyun

AU - Eom, Hyeon Seok

AU - Lee, Hyewon

AU - Lee, Won Sik

AU - Shin, Ho Jin

AU - Lee, Ji Hyun

AU - Park, Yong

AU - Jo, Jae Cheol

AU - Do, Young Rok

AU - Mun, Yeung Chul

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, ß2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.

AB - Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, ß2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.

KW - Inflammation

KW - Multiple myeloma

KW - Prognosis

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84942092210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942092210&partnerID=8YFLogxK

U2 - 10.3904/kjim.2015.30.5.675

DO - 10.3904/kjim.2015.30.5.675

M3 - Article

VL - 30

SP - 675

EP - 683

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 5

ER -